Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan

Blood (2024) 144 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2024-198992

Published: 2024

Journal Articles

Copy Number Alterations of Chromosome 9p24.1 in Elderly Patients with Advanced-Stage Classic Hodgkin Lymphoma Who Received ABVD: An Ancillary Analysis of Multi-Center Retrospective Study in Japan (HORIZON study)

Blood (2022) 140 (Supplement 1): 11890–11892.

https://doi.org/10.1182/blood-2022-164977

Published: 2022

Journal Articles

Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia

Kenshi Suzuki, Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu

Blood (2021) 138 (Supplement 1): 1352.

https://doi.org/10.1182/blood-2021-146744

Published: 2021

Journal Articles

Oncofetal Protein SALL4 Is Highly Expressed in Myelodysplastic Syndrome Alongside with NAT10 and P53

Hiro Tatetsu, MD, Miho Watanabe, MD, Emily F Mason, MD PhD, Scott B Lovitch, MDPhD, Kenji Tokunaga, MD, Eisaku Iwanaga, MD, Masao Matsuoka, MDPhD, Daniel G. Tenen, MD, Li Chai, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-134533

Published: 2020

Journal Articles

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

Wataru Munakata, Naohiro Sekiguchi, MD PhD, Rai Shinya, MD,PhD, Kenshi Suzuki, MD PhD, Hiroshi Handa, MD PhD, Hirohiko Shibayama, MD PhD, Tomoyuki Endo, MD PhD, Yasuhito Terui, MD PhD, Noriko Iwaki, MD PhD, Noriko Fukuhara, MD PhD, Hiro Tatetsu, MD PhD, Shinsuke Iida, MD PhD, Takayuki Ishikawa, MD PhD, Ryota Shiibashi, Koji Izutsu, MD PhD

Blood (2019) 134 (Supplement_1): 345.

https://doi.org/10.1182/blood-2019-124614

Published: 2019

Journal Articles

PU.1-Induced IRF4 Down-Regulation and Subsequent IRF7 up-Regulation in Myeloma Cells

Niina Ueno, MD, Shikiko Ueno, MD PhD, Shinya Endo, MD, Nao Nishimura, MD, Hiro Tatetsu, MD PhD, Shinya Hirata, MD PhD, Hiroaki Mitsuya, MD PhD, Yutaka Okuno, MD PhD

Blood (2015) 126 (23): 2957.

https://doi.org/10.1182/blood.V126.23.2957.2957

Published: 2015

Journal Articles

Conditional Knockout of Sfpi1 in Post GC B and Plasma Cells Induces B Cell Lymphoma and Plasma Cell Neoplasm

Shinya Endo, MD, Hiromichi Yuki, MD PhD, Yoshihiro Komohara, MD PhD, Shikiko Ueno, MD PhD, Nao Nishimura, MD, Niina Ueno, MD, Hiro Tatetsu, MD PhD, Motohiro Takeya, MD PhD, Hiroyuki Hata, MD PhD, Seiji Okada, MD PhD, Daniel G. Tenen, MD, Hiroaki Mitsuya, MD PhD, Yutaka Okuno, MD PhD

Blood (2014) 124 (21): 29.

https://doi.org/10.1182/blood.V124.21.29.29

Published: 2014

Journal Articles

SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+ Cells

Hiro Tatetsu, MD PhD, Fei Wang, Chong Gao, MD PhD, Shikiko Ueno, MD PhD, Xi Tian, BS, Myriam Armant, PhD, Alex Federation, Jun Qi, PhD, James E. Bradner, Daniel G. Tenen, MD, Li Chai, MD

Blood (2014) 124 (21): 1566.

https://doi.org/10.1182/blood.V124.21.1566.1566

Published: 2014

Journal Articles

Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex

Chong Gao, Todor Dimitrov, Kol Jia Yong, Hiro Tatetsu, Ha-won Jeong, Hongbo R. Luo, James E. Bradner, Daniel G. Tenen, Li Chai

Blood (2013) 121 (8): 1413–1421.

https://doi.org/10.1182/blood-2012-04-424275

Published: 2013

Includes: Supplemental data

Journal Articles

PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells

Hiromichi Yuki, Shikiko Ueno, Hiro Tatetsu, Hiroaki Niiro, Tadafumi Iino, Shinya Endo, Yawara Kawano, Yoshihiro Komohara, Motohiro Takeya, Hiroyuki Hata, Seiji Okada, Toshiki Watanabe, Koichi Akashi, Hiroaki Mitsuya, Yutaka Okuno

Blood (2013) 121 (6): 962–970.

https://doi.org/10.1182/blood-2012-05-431429

Published: 2013

Includes: Supplemental data

Journal Articles

A Novel Approach in Expanding CD34+CD90+ and CD34+CD38-CD90+ Cells Associated with Enhanced in Vivo Repopulating potential.

Hiro Tatetsu, MD, PhD, Chong Gao, MD, PhD, Shikiko Ueno, MD, PhD, Daniel G Tenen, MD, Li Chai, MD

Blood (2012) 120 (21): 2337.

https://doi.org/10.1182/blood.V120.21.2337.2337

Published: 2012

Journal Articles

PU.1-Induced Growth Arrest and Apoptosis in Classical Hodgkin Lymphoma Cells

Hiromichi Yuki, MD, Shikiko Ueno, MD, PhD, Hiroaki Niiro, MD, PhD, Hiro Tatetsu, MD, PhD, Hiroyuki Hata, MD, PhD, Toshiki Watanabe, MD, PhD, Seiji Okada, MD, Ph.D, Koichi Akashi, MD, PhD., Hiroaki Mitsuya, Professor, Yutaka Okuno, MD, PhD

Blood (2011) 118 (21): 2628.

https://doi.org/10.1182/blood.V118.21.2628.2628

Published: 2011

Journal Articles

Decreased CD138 Expression in Myeloma Cells: A Potential Indicator of Poor Prognosis and Aberrant Differentiation,

Yawara Kawano, MD, Shiho Fujiwara, MD, Hiromichi Yuki, MD, Hiro Tatetsu, MD, PhD, Hiroshi Yamasaki, MD, PhD, Akira Sakai, MD, PhD, Yutaka Okuno, MD, PhD, Hiroaki Mitsuya, MD, PhD, Hiroyuki Hata, MD, PhD

Blood (2011) 118 (21): 3939.

https://doi.org/10.1182/blood.V118.21.3939.3939

Published: 2011

Journal Articles

Conditionally Expressed PU.1 Transactivates TRAIL Gene and Induces Apoptosis in Myeloma Cell Lines.

Shikiko Ueno, Hiro Tatetsu, Hiroyuki Hata, MD, PhD, Tadafumi IIno, Hiroaki Niiro, Koichi Akashi, MD, PhD, Daniel G. Tenen, MD, Hiroaki Mitsuya, Yutaka Okuno

Blood (2008) 112 (11): 1676.

https://doi.org/10.1182/blood.V112.11.1676.1676

Published: 2008

Journal Articles

Microarray Analysis of PU.1-Induced Growth Arrest and Apoptosis of Myeloma Cell Lines.

Shikiko Ueno, Hiro Tatetsu, Naoko Harada, Hiroyuki Hata, Tadafumi Iino, Hiroaki Niiro, Koichi Akashi, Daniel G. Tenen, Hiroaki Mitsuya, Yutaka Okuno

Blood (2007) 110 (11): 2499.

https://doi.org/10.1182/blood.V110.11.2499.2499

Published: 2007

Journal Articles

PU.1 Is Downregulated in a Subset of Multiple Myeloma by the Methylation of Its -17 kb Upstream Regulatory Region and the Promoter.

Yutaka Okuno, MD, PhD, Hiro Tatetsu, MD.PhD., Shikiko Ueno, MD., Hiroyuki Hata, MD.PhD., Yasuhiro Yamada, MD.PhD., Motohiro Takeya, MD.PhD., Tadafumi Iino, MD, Koichi Akashi, MD.PhD., Daniel G. Tenen, MD., Hiroaki Mitsuya, MD.PhD.

Blood (2006) 108 (11): 3417.

https://doi.org/10.1182/blood.V108.11.3417.3417

Published: 2006

Journal Articles

Downregulation of PU.1 Is Required for Subtype of Multiple Myeloma.

Hiro Tatetsu, MD, Hiroyuki Hata, MD.PhD., Yasuhiro Yamada, MD, Hiroaki Mitsuya, MD.PhD, Yutaka Okuno, MD.PhD

Blood (2005) 106 (11): 3401.

https://doi.org/10.1182/blood.V106.11.3401.3401

Published: 2005

Journal Articles

Both 5′ and 3′ Distal Regulatory Elements Are Required for Human CD34 Gene Expression.

Yutaka Okuno, MD. PhD, Elena Levantini, PhD, Hiro Tatetsu, MD, Hiroaki Mitsuya, MD. PhD, Daniel G. Tenen, MD

Blood (2004) 104 (11): 3554.

https://doi.org/10.1182/blood.V104.11.3554.3554

Published: 2004

NARROW

Treatment and Outcomes of Stage I-II Pulmonary MALT Lymphoma: A Multi-Institutional Observational Study in Japan

Copy Number Alterations of Chromosome 9p24.1 in Elderly Patients with Advanced-Stage Classic Hodgkin Lymphoma Who Received ABVD: An Ancillary Analysis of Multi-Center Retrospective Study in Japan (HORIZON study)

Oncofetal Protein SALL4 Is Highly Expressed in Myelodysplastic Syndrome Alongside with NAT10 and P53

Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström Macroglobulinemia

PU.1-Induced IRF4 Down-Regulation and Subsequent IRF7 up-Regulation in Myeloma Cells

Conditional Knockout of Sfpi1 in Post GC B and Plasma Cells Induces B Cell Lymphoma and Plasma Cell Neoplasm

SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+ Cells

Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex

PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells

A Novel Approach in Expanding CD34+CD90+ and CD34+CD38-CD90+ Cells Associated with Enhanced in Vivo Repopulating potential.

PU.1-Induced Growth Arrest and Apoptosis in Classical Hodgkin Lymphoma Cells

Decreased CD138 Expression in Myeloma Cells: A Potential Indicator of Poor Prognosis and Aberrant Differentiation,

Conditionally Expressed PU.1 Transactivates TRAIL Gene and Induces Apoptosis in Myeloma Cell Lines.

Microarray Analysis of PU.1-Induced Growth Arrest and Apoptosis of Myeloma Cell Lines.

PU.1 Is Downregulated in a Subset of Multiple Myeloma by the Methylation of Its -17 kb Upstream Regulatory Region and the Promoter.

Downregulation of PU.1 Is Required for Subtype of Multiple Myeloma.

Both 5′ and 3′ Distal Regulatory Elements Are Required for Human CD34 Gene Expression.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only